Reliance Life Sciences Pvt. Ltd.
Infliximab Immunology & rheumatology
Originator: Remicade · Janssen Biotech / Johnson & Johnson (originally Centocor); initial U.S. approval 1998
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| InflixiRel | 100 mg vial | — | — | — | — |
Rituximab Cancer (oncology)
Originator: Rituxan · Genentech, Inc. (a member of the Roche Group), with Biogen; Rituxan is jointly marketed by Biogen and Genentech USA in the US; MabThera is marketed by Roche
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| RituxiRel | 100 mg/10 mL and 500 mg/50 mL single-use vials | — | — | — | — |
This page is an information resource for healthcare professionals, licensed importers and patients under medical care. It is not medical advice, not a prescription service, and not an offer to sell prescription medicines to the public.
Need a verified quotation?
Send us the molecule, strength, pack size, quantity and destination country. We reply with a batch-traceable quotation, certificates of analysis and shipping documentation.
We supply licensed pharmacies, hospitals, importers and distributors — not direct-to-consumer patients.